v3.26.1
SEGMENT INFORMATION (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
SCHEDULE OF SIGNIFICANT EXPENSE CATEGORIES

The table below summarizes the significant expense categories regularly reviewed by the CODM (in thousands):

 

           
   For the three months ended March 31, 
   2026   2025 
         
Product revenue, net  $8,720   $— 
           
Cost of sales   2,696    — 
           
Research and development costs          
Salaries & related costs   1,733    4,681 
Non-cash stock-based compensation   223    670 
Other research and development costs (a)   7,599    4,590 
Total research and development costs   9,555    9,941 
           
General and administrative costs          
Salaries & related costs   8,345    3,653 
Non-cash stock-based compensation   2,734    2,031 
Commercial costs   1,802    1,207 
Other general and administrative costs (b)   6,621    2,895 
Total general and administrative costs   19,502    9,786 
           
Other segment items (c)   5,958    7,698 
Net loss  $(17,075)  $(12,029)

 

(a) Other research and development costs include, but are not limited to preclinical lab supplies, preclinical and development costs, clinical trial costs, preclinical manufacturing and manufacturing facility costs, costs associated with preclinical regulatory approvals, preclinical depreciation on lab supplies and manufacturing facilities, and preclinical consultant-related expenses.
(b) Other selling, general and administrative costs primarily consist of office facility costs, public company reporting related costs, professional fees (e.g., legal expenses), regulatory costs, production costs not attributable to cost of sales and other general operating expenses not otherwise included in research and development expenses.
(c) Other segment items include interest income, interest expense, change in fair value of warrant liabilities, other income and income tax (benefit) expense.